Market Overview

Repros Therapeutics Says FDA Granted End of Phase 2 Meeting in Late May to Discuss Proellex(R)-V Phase 2 Design

Related RPRX
Wall Street's M&A Chatter From December 12: Fox-Disney, Repros Therapeutics-Allergan, Agrium-Macrofertil
A Peek Into The Markets: U.S. Stock Futures Mostly Higher Ahead Of Fed Meeting
Prospects dim for European approval of Repros' enclomiphene for secondary hypogonadism; shares down 10% after hours (Seeking Alpha)

Repros Therapeutics Inc.^® (Nasdaq: RPRX) today announced that the FDA has agreed to a Type B meeting scheduled for the last half of May to discuss the Phase 3 development of Proellex® as a vaginally administered product for the treatment of uterine fibroids. During the meeting, Repros will discuss the proposed plans for a Phase 3 study, the FDA's requirements for the size of the safety population and the adequacy of the already completed preclinical studies to support a marketing application.

Once the meeting is held, the Company will report the outcome to the financial community in a timely fashion.

Posted-In: News FDA


Related Articles (RPRX)

View Comments and Join the Discussion!

Partner Center